Subtype
Ovarian Serous Adenocarcinoma
CI-CAN-00006254Explore in graph →
69 active trials7 evidence items
- NCIt
- C7550
- OncoTree
- SOC
- DOID
- 0050933
- UMLS CUI
- C1335177
- Other
- 1 more code
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00006254Explore in graph →
Clinical trials
151 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (20)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05451849 | A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer | terminated | Phase 1 / Phase 2 | 14 | TCR2 TherapeuticsINDUSTRY | 1 | Jul 13, 2026 | clinicaltrials |
| NCT05001282 | A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα) | terminated | Phase 1 / Phase 2 | 79 | Elucida OncologyINDUSTRY | 1 | Aug 7, 2024 | clinicaltrials |
| NCT05538624 |
| A Study of Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma of the Ovary |
| terminated |
| Phase 1 / Phase 2 |
| 14 |
| Avenge Bio, IncINDUSTRY |
| 1 |
| Apr 24, 2024 |
| clinicaltrials |
| NCT03924245 | Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers | terminated | Phase 1 | 3 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Apr 4, 2022 | clinicaltrials |
Data updated 22 days agoSource updated Jul 13, 2026source: clinicaltrials